AI 聊天
Loading data for REVB — first visit, this takes a few seconds.

Revelation Biosciences, Inc.

REVB · NasdaqCM · USD

0.99 -0.01 (-1.00%)

收盘价: Sep 14, 2026, 3:58 PM

市值
$3.88M
成交量
3.44K
下次财报日期
Nov 5, 2026

Revelation Biosciences, Inc.(REVB)股价、分析与数据

内在价值

正在加载内在价值…

分析师预测

股票预测 →

分析师预测不可用

12个月目标价 · n/a 位分析师

分析师一致意见: n/a

时间间隔:1D
正在加载K线和信号…

财务表现

查看财务 →

加载中...

最新财报

已公布较预期同比变动
营收$0n/an/a
每股收益(TTM)-$0,87-$0,04+96.90%

下次财报

盘中。

预估 · 升级 →

查看财报详情 →

指标

买价
0.68
市值
3.88M
净利润(TTM)
-19.2M
-0.14
27.03
0.04
-0.34
市净率(TTM)
0.38
市销率(TTM)
n/a
财报日期
Nov 5, 2026
卖价
1.29
成交量
3,445
20日均量
41,020
开盘价
1.00
前收盘价
1.00
日内区间
0.99 - 1.00
52周区间
0.88 - 7.60
分红
n/a
除息日
n/a

关于 Revelation Biosciences, Inc.

查看公司资料 →
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California. Biotechnology · Healthcare

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

板块 Healthcare
上市日期 Nov 17, 2020
员工人数 8
交易所 NasdaqCM
股票代码 REVB